Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein

A non-human mammal, genetic modification technology, applied in the field of genetically modified non-human mammals produced by multi-cycle electroporation of CAS9 protein, can solve the problem of unsuccessful germline transmission

Inactive Publication Date: 2019-03-01
JACKSON LAB THE
View PDF22 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a follow-up experiment using a high-salt medium designed to increase the total energy delivered during the pulse of electroporation, the authors again report preliminary data suggesting that germline transmission was unsuccessful

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
  • Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
  • Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0256] Example 1 Electroporation of mouse zygotes and putative zygotes with reporter-encoding polynucleotides

[0257] This experiment describes the results of electroporation of mouse zygotes or putative zygotes ("zygotes" for short) with a reporter-gene-encoding plasmid.

[0258] The pMAXGFP vector (Lonza, USA) carrying the CMV promoter and SV40 polyadenylation signal supporting ubiquitous expression was chosen for this experiment. B6D2F2 mouse embryos were collected and treated in acidic Tyrode solution (AT) (P / N T1788, SigmaAldrich) for 5 s, washed twice in KOSMaa / BSA (P / N Zeks-050, Zenith Biotech), and placed in 25 μL of Opti-MEM (P / N 31985, Life Technologies). Embryos in 25 μL were then mixed with an equal volume (25 μL) of 80 ng / μL of pMAXGFP in TE buffer (10 mM Tris, 0.1 mM EDTA, pH 7.5) to achieve a final DNA concentration of 40 ng / μL, and the mixture was Load into a 1-mm shock cuvette and perform electroporation using the following settings: 30 V, pulse duration 1 ...

Embodiment 2

[0262] Example 2 Electroporation of mouse zygotes and putative zygotes with CRISPR / Cas system

[0263] This experiment demonstrates the use of the methods of the present invention to deliver the CRISPR / Cas system to mouse zygotes or putative zygotes ("zygotes" for short) for CRISPR / Cas-mediated targeted gene disruption.

[0264] For this purpose, Tet1 exon 4 and Tet2 exon 3 were selected as targets using the aforementioned guide RNAs (Wang et al., 2013, incorporated herein by reference). The Tet1 and Tet2 systems are convenient in that the Sac1 (Tet1) or EcoRV (Tet2) restriction sites overlap with the PAM (protospacer adjacent motif) proximal sequence. Therefore, restriction fragment length polymorphism (RFLP) analysis can be used to detect mutant alleles using PCR products containing the target site amplified from embryos (Wang et al., 2013).

[0265] In Experiment 6, mouse B6D2F2 zygotes were first treated with AT for 10 s, mixed with 40 / 20 ng / μL or 100 / 50 ng / μL of Cas9 mRN...

Embodiment 3

[0273] The development of the mouse zygote of embodiment 3 electroporation

[0274] The in vitro culture and analysis of zygotes is an important method based on which a large number of parameters related to gene editing technologies can be tested and analyzed with a fast turnaround time and preferably low operating costs. However, when electroporated zygotes were cultured using conventional in vitro culture systems, subsequent embryonic development appeared to be arrested or aborted. Typically, after electroporation of Cas9 mRNA / sgRNA at different concentration ranges (e.g., 50 / 25ng / μL to 1000 / 500ng / μL), at the end of the 3.5-day culture period, embryos progressed to different developmental stages, including 1-cell , 2-cell or 4-cell stage, morula stage and occasionally blastocyst stage (Experiment 8). In contrast, control embryos that were not electroporated reached the blastocyst stage at the end of the same time period, whether or not the control embryos were pretreated wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention described herein provides high throughput methods and reagents for generating transgenic animals (e.g., non-human mammals) through introducing a CRISPR / Cas9 system comprising a Cas9 protein into gametes or preimplantation stage embryos (e.g., one-cell embryos or zygotes) via multiple cycles (e.g., 4- 10 cycles) of electroporation, leading to genetically inheritable modification to the genome of the animal.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of the filing date of U.S. Provisional Application No. 62 / 279,023, filed January 15, 2016, under 35 U.S.C. § 119(e). This application is also related to International Application No. PCT / US2015 / 052928, filed September 29, 2015, which is required under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 056,687, filed September 29, 2014 Benefits on filing date. The entire content of each of the above-cited applications is incorporated herein by reference. [0003] governmental support [0004] The invention described herein was made with United States Government support under grant number P30CA034196 awarded by the National Cancer Institute of the NIH. The US Government has certain rights in this invention. Background technique [0005] Delivery of biological or genetic material into mammalian zygotes is often the first step in modifying mammalian genomes, such as the creati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A01K67/027C12N15/87C12N15/873
CPCA01K67/0275C12N15/87C12N15/873A01K2217/00A01K2227/105A01K2267/0306A01K2267/0331C12N9/22A01K2207/10A01K2217/072C12N15/907C12N2310/20A61D19/04A61N1/327C12N15/11C12N15/8509C12N2015/8536C12N2710/16143C12N2710/22043C12N2800/80
Inventor 王皓毅W-B·王
Owner JACKSON LAB THE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com